BioCentury
ARTICLE | Company News

AstraZeneca, Isis expand antisense collaboration

August 4, 2015 12:53 AM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN) and Isis Pharmaceuticals Inc. (NASDAQ:ISIS) partnered to discover and develop antisense therapeutics against undisclosed targets for cardiovascular, metabolic and renal diseases.

Isis spokesperson Amy Blackley said Isis will be responsible for discovery, and AstraZeneca will lead development once candidates are selected. ...